Abstract: The present invention relates to the field of vitamin D insufficiency and deficiency, viz. too low blood levels of 25(OH)D, and to their prevention and treatment. It provides a vitamin D supplement which comprises (i) a combination of 25(OH)D3 and/or 25(OH)D2 and vitamin D2; or (ii) a combination of 25(OH)D3 and/or 25(OH)D2 and vitamin D3; or (iii) a combination of 25(OH)D3 and/or 25(OH)D2 and a combination of vitamin D2 and vitamin D3, for use in the treatment of and/or prophylaxis of vitamin D insufficiency or deficiency in obese persons, overweight persons having the tendency to get obese or persons having a history of malabsorption of vitamin D or persons with a genetic disposition to develop obesity. Also provided are corresponding compositions and dosage regimens comprising such vitamin D supplements as well as kits comprising such compositions. Furthermore, corresponding dosage regimens for daily administration and corresponding product package inserts are also provided.

Abstract: Methods for enhancing the ability of an individual, exposed to sunlight, to produce vitamin D via the skin. Pharmaceutical compositions comprising provitamin D and at least one of lumisterol and tachysterol and analogs and derivatives thereof are also disclosed.

Abstract: Methods for enhancing the ability of an individual, exposed to sunlight, to produce vitamin D via the skin. Pharmaceutical compositions comprising provitamin D and at least one of lumisterol and tachysterol and analogs and derivatives thereof are also disclosed.

Abstract: Methods for enhancing the ability of an individual, exposed to sunlight, to produce vitamin D via the skin. Pharmaceutical compositions comprising provitamin D and at least one of lumisterol and tachysterol and analogs and derivatives thereof are also disclosed.

Abstract: The present invention is directed to the use of thyroid hormone conversion inhibitors to treat hyperproliferative skin disorders, preferably their use in topical admixtures.

Abstract: Methods for enhancing the ability of an individual, exposed to sunlight, to produce vitamin D via the skin. Pharmaceutical compositions comprising provitamin D and at least one of lumisterol and tachysterol and analogs and derivatives thereof are also disclosed.

Abstract: Disclosed are glycosides, orthoester glycosides and glycuronamides of fluoxetine and analogs thereof to treat conditions and diseases such as depression.

Abstract: Androgen glycosides provide free, circulatory androgen on oral administration as they are subject to less, first pass breakdown by the liver.

Abstract: Methods for inhibiting, preventing, or treating cancer cell growth are disclosed. In one embodiment, the method comprises the step of administering to a patient an effective amount of a metabolic precursor of 1,25-dihydroxyvitamin D, or an analog or a derivative thereof, to increase levels of the metabolic precursor available to a target cell. In a preferred embodiment, the metabolic precursor is 25-hydroxyvitamin D.

Abstract: Methods are disclosed for the regulation of cell differentiation and proliferation, e.g., for treating hyperproliferative skin disorders, such as psoriasis, for enhancing wound healing, for stimulating hair growth and inhibiting hair growth, by topical administration of parathyroid hormone (PTH), parathyroid related peptide (PTHrP), or fragment, analog or derivative thereof, and salts thereof, encapsulated by liposomes.

Abstract: Methods are disclosed for the regulation of cell differentiation and proliferation, e.g., for treating hyperproliferative skin disorder, such as psoriasis, and skin cancer for enhancing wound healing, for stimulating hair growth and inhibiting hair growth, by administration of nucleic acid molecules encoding parathyroid hormone (PTH), parathyroid related peptide (PTHrP), or fragment, analog or derivative thereof, and salts thereof, encapsulated by particular liposomes or incorporated into a porous biocompatable matrix.

Abstract: Methods for enhancing the ability of an individual, exposed to sunlight, to produce vitamin D via the skin. Pharmaceutical compositions comprising provitamin D and at least one of lumisterol and tachysterol and analogs and derivatives thereof are also disclosed.

Abstract: Androgen glycosides provide free, circulatory androgen on oral administration as they are subject to less, first pass breakdown by the liver.

Abstract: Androgen glycosides provide free, circulatory androgen on oral administration as they are subject to less, first pass breakdown by the liver.

Abstract: Biotin, fluorescent and chemiluminescent labeled vitamin D compounds are disclosed as well as their use in assays for the presence of vitamin D, its metabolites and vitamin D analogs in biological fluids.

Abstract: Biotin, fluorescent and chemiluminescent labeled vitamin D compounds are disclosed as well as their use in assays for the presence of vitamin D, its metabolites and vitamin D analogs in biological fluids.

Abstract: Glycosides and orthoester glyco side derivatives of bisphosphonate compounds useful for treating and/or preventing hypercalcaemia of malignancy, Paget's disease, osteoporosis, metastatic cancer in bone and soft tissue and periodontal disease have markedly enhanced intestinal absorption and enhanced bioavailability.

Abstract: Serum levels of therapeutically useful glucocorticosteroids are substantially increased by oral administration of the corresponding glycoside or orthoester glycoside.

Abstract: Kit comprising biotin, fluorescent and chemiluminescent labeled vitamin D compounds are disclosed. The disclosed kit may be used in assays for the presence of vitamin D, its metabolites and vitamin D analogs in biological fluids.

Abstract: Kit comprising biotin, fluorescent and chemiluminescent labeled vitamin D compounds are disclosed. The disclosed kit may be used in assays for the presence of vitamin D, its metabolites and vitamin D analogs in biological fluids.